[Dose-response study of preincisional buprenorphine on emergence time and postoperative analgesic requirement in patients anesthetized with sevoflurane].
The effect of intravenous buprenorphine on emergence time from sevoflurane anesthesia and postoperative analgesic requirement was evaluated after otolaryngeal surgeries. Forty-five patients were randomly assigned to one of three treatment groups (n = 15 each): Control-group received saline as a control; 2 micrograms-group received buprenorphine 2 micrograms.kg-1; and 4 micrograms-group received buprenorphine 4 micrograms.kg-1, respectively. Study drug was administered intravenously at the induction of general anesthesia. Anesthesia was maintained with sevoflurane (1.5%) and nitrous oxide (66%) in oxygen. The pain score, postoperative analgesic requirement, and incidence of nausea and/or vomiting were examined. The emergence times were 16.4 +/- 3.5, 14.7 +/- 5.2, and 17.8 +/- 7.7 min [mean +/- SD], in the control-group, the 2 micrograms-group, and the 4 micrograms-group, respectively. There were no differences among the groups in term of the end-tidal sevoflurane concentration immediately before tracheal extubation. In the control-group, the 2 micrograms-group, and the 4 micrograms-group, 10, 1, and 3 patients, requested additional analgesics during the first 24 hours after surgery, respectively (control-group vs. 2 micrograms-group and 4 micrograms-group, P < 0.05). Nausea and vomiting occurred more frequently in the 2 micrograms-group and the 4 micrograms-group. We conclude that buprenorphine (2 or 4 micrograms.kg-1) reduced analgesic requirement during the first 24 hours after surgery without delaying emergence from sevoflurane anesthesia.
Takahashi
S
S
Department of Anesthesia, Institute of Clinical Medicine, University of Tsukuba.
Tanaka
M
M
Matsumiya
N
N
Kondo
T
T
Miyabe
M
M
Toyooka
H
H
D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000762:Anesthesia Recovery Period; D000768:Anesthesia, General; D002047:Buprenorphine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008738:Methyl Ethers; D008875:Middle Aged; D013517:Otorhinolaryngologic Surgical Procedures; D010149:Postoperative Pain / Q000188:drug therapy*; D020250:Postoperative Nausea and Vomiting / Q000139:chemically induced / Q000453:epidemiology; D011229:Preanesthetic Medication; D000077149:Sevoflurane; D016896:Treatment Outcome
D000701:Analgesics, Opioid; D008738:Methyl Ethers; D000077149:Sevoflurane; D002047:Buprenorphine